Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 in San Francisco. Krish S. Krishnan, chairman and CEO, is scheduled to present at 10:30 am ET / 7:30 am PT and will host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:30 am ET / 7:30 am PT on January 12, 2026 and will be posted in the Investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – KRYS
On the day this news was published, KRYS declined 0.89%, reflecting a mild negative market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $67M from the company's valuation, bringing the market cap to $7.48B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves today: ARWR up 2.25%, while ACAD, ACLX, MIRM, and MTSR are down between 0.34% and
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference participation | Neutral | +0.8% | Announcement of Evercore healthcare conference appearance and webcast details. |
| Nov 03 | Earnings results | Positive | +0.2% | Reported strong Q3 2025 revenue, margins, cash and global VYJUVEK rollout. |
| Oct 21 | Earnings schedule | Neutral | -2.6% | Scheduled Q3 2025 results call and provided webcast and replay information. |
| Oct 14 | Regulatory designation | Positive | +1.8% | FDA platform technology designation for HSV-1 vector used in KB801. |
| Sep 15 | FDA label update | Positive | +8.4% | FDA approval of updated VYJUVEK label expanding eligibility and at-home use. |
KRYS has generally reacted positively to substantial regulatory and label updates, while routine conference and scheduling announcements have produced modest or mixed price responses.
Over the last few months, Krystal Biotech has combined strong fundamentals with meaningful regulatory progress. Q3 2025 results highlighted VYJUVEK net product revenue of $97.8M and total revenue since U.S. launch of $623.2M, with a 96% gross margin. FDA approval of an updated VYJUVEK label for newborns and self-application drove a 8.37% move, underscoring the market’s focus on label expansion. Platform technology designation for the HSV-1 vector also saw a positive reaction. In contrast, prior conference participation and results-call scheduling produced relatively modest price changes, similar in nature to today’s conference appearance announcement.
Market Pulse Summary
This announcement signals Krystal Biotech’s participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, with a management presentation at 10:30 am ET. It follows a period of strong operating performance, including robust VYJUVEK revenue and favorable regulatory milestones such as the updated label approval. Investors may focus on any incremental commentary delivered at the conference, but this notice itself introduces no new financial, clinical, or regulatory data.
AI-generated analysis. Not financial advice.
PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a presentation at 10:30 am ET / 7:30 am PT and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 10:30 am ET / 7:30 am PT on Monday, January 12, 2026 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
FAQ
When will Krystal Biotech (KRYS) present at the J.P. Morgan Healthcare Conference?
Who will present for Krystal Biotech (KRYS) at the January 12, 2026 conference?
Will Krystal Biotech (KRYS) host investor meetings at the J.P. Morgan conference?
How can investors watch Krystal Biotech's (KRYS) presentation on January 12, 2026?
What time is Krystal Biotech's (KRYS) webcast for investors in Pacific Time?
Where will the Krystal Biotech (KRYS) presentation take place during the J.P. Morgan conference?
